Eriguchi M, Osada I, Fujii Y, Takeda Y, Yoshizaki I, Akiyama N, Yanagie H, Sekiguchi M, Kizu R, Matsushita H, Mathé G
Department of Surgery, University of Tokyo, Japan.
Biomed Pharmacother. 1997;51(5):217-20. doi: 10.1016/s0753-3322(97)81599-5.
A new DACH platinum complex, l-OHP, was developed by Kidani as an anticancer agent. A clinical trial took place in Europe which demonstrated its therapeutic efficacy for colorectal cancer. An effective treatment, especially chemotherapy for patients with a advanced scirrhous type gastric cancer, has not yet been established. An in vitro study showed that l-HOP inhibited cell growth in human gastric cancer cell lines. Our pilot study determined the efficacy of preoperative administration of l-OHP, 67 mg/m2 to 100 mg/m2, every 2-3 weeks, for two to three cycles, in five patients with this disease (Stage III and IV) roentogenoscopically and histologically. The platinum concentration in the tissues was also measured. By X-ray examination of the stomach at the time of pre- and post-administration of l-OHP, extension of the lesional gastric wall was observed. Histologically three Grade 2 responses and two Grade 1a responses were obtained according to the criteria presented by Japanese Research Society for Gastric Cancer. The mean platinum concentrations in the lesional tissues were 0.98 ppm and 0.5 ppm in the patients administered l-OHP for three and two cycles respectively. There was no toxicity that prevented surgery. These preliminary results showed the possibility that 1-OHP would be effective for patients with advanced scirrhous type gastric cancer as a neoadjuvant therapy.
一种新的DACH铂络合物，即奥沙利铂（l-OHP），由木谷达仁研发作为一种抗癌剂。在欧洲进行了一项临床试验，证明了其对结直肠癌的治疗效果。对于晚期硬癌型胃癌患者，尚未确立有效的治疗方法，尤其是化疗方法。一项体外研究表明，奥沙利铂抑制人胃癌细胞系中的细胞生长。我们的初步研究确定了对5例该疾病（III期和IV期）患者每2至3周术前给予67mg/m²至100mg/m²的奥沙利铂，共两至三个周期，通过X线透视和组织学检查其疗效。还测量了组织中的铂浓度。通过在给予奥沙利铂前后对胃部进行X线检查，观察到病变胃壁的扩展。根据日本胃癌研究会提出的标准，组织学上获得了3例2级反应和2例1a级反应。接受三个周期和两个周期奥沙利铂治疗的患者病变组织中的铂平均浓度分别为0.98ppm和0.5ppm。没有出现妨碍手术的毒性反应。这些初步结果表明，奥沙利铂作为新辅助治疗对晚期硬癌型胃癌患者可能有效。
